We found that patients with mRNA BCL2 high expression had a better prognosis than low expression in TCGA LUAD, TCGA lung cancer, GSE37745, and GSE37745 cohorts (Figures 8C–F; P < 0.05). This evidence concerns the gene BCL2 and lung cancer.